CVS Pharmacology: Antianginal Drugs

Introduction/Overview

Angina pectoris represents a clinical manifestation of myocardial ischemia precipitated by an imbalance between oxygen supply and demand. The therapeutic objective of antianginal pharmacotherapy is to restore this balance by modifying coronary circulation, reducing myocardial oxygen consumption, or both. The importance of this therapeutic class is underscored by the prevalence of coronary artery disease worldwide and the consequent morbidity and mortality associated with unstable angina and myocardial infarction. Mastery of antianginal pharmacology is essential for clinicians and pharmacists to optimize patient outcomes, tailor therapy to individual pathophysiology, and anticipate interactions and adverse events.

Learning Objectives

• Identify the major drug classes employed for angina management and their distinguishing chemical features.
• Describe the pharmacodynamic mechanisms underlying the therapeutic effects of each antianginal agent.
• Summarize the pharmacokinetic profiles that inform dosing regimens and drug selection.
• Recognize common and serious adverse reactions, as well as contraindications and drug–drug interaction risks.
• Apply pharmacologic principles to special patient populations, including those with renal, hepatic, or cardiac comorbidities.

Classification

Drug Classes and Categories

Antianginal agents are traditionally grouped into the following categories:

• Beta‑adrenergic receptor antagonists (beta blockers)
• Calcium channel blockers (CCBs)
• Nitrates and nitrate prodrugs
• Phosphodiesterase‑5 inhibitors (particularly sildenafil)
• Ranolazine and other metabolic modulators
• Other agents (e.g., nicorandil, ivabradine)

Each class exhibits distinct pharmacologic actions that address either the oxygen demand side (myocardial contractility, heart rate) or the oxygen supply side (coronary vasodilation, blood flow redistribution).

Chemical Classification

From a structural standpoint, beta blockers are characterized by an aryloxypropanolamine core; CCBs contain a dihydropyridine, phenylalkylamine, or benzothiazepine scaffold; nitrates are organic esters of nitric acid; phosphodiesterase inhibitors possess a cyclic guanosine monophosphate (cGMP)–modulating motif; ranolazine is a 2,3‑dihydroxy‑3‑methyl‑1‑pyrrolidinyl‑3‑methyl‑2‑(3‑phenylpropyl)‑1,3‑di‑pyridine derivative; nicorandil combines a nitrate moiety with a potassium channel opener. These chemical distinctions underpin the pharmacokinetic and pharmacodynamic differences observed in clinical practice.

Mechanism of Action

Beta‑Adrenergic Receptor Antagonists

Beta blockers attenuate sympathetic stimulation by competitively inhibiting β₁ and/or β₂ adrenergic receptors on myocardial cells, thereby reducing intracellular cyclic adenosine monophosphate (cAMP) levels. The downstream effects include decreased sarcoplasmic reticulum calcium release, diminished intracellular calcium concentration, and reduced myocardial contractility (negative inotropy). Heart rate deceleration (negative chronotropy) further lowers myocardial oxygen consumption. In addition, beta blockers suppress renin release from juxtaglomerular cells, providing ancillary blood pressure–lowering benefits.

Calcium Channel Blockers

CCBs impede voltage‑gated L‑type calcium channels in vascular smooth muscle and cardiac myocytes. Dihydropyridines preferentially dilate coronary and peripheral arterioles, enhancing subendocardial perfusion, while phenylalkylamines and benzothiazepines exhibit both vasodilatory and negative inotropic effects. The net result is decreased afterload and myocardial oxygen demand, alongside improved coronary blood flow.

Nitrates and Nitrate Prodrugs

Nitrates undergo metabolic conversion to nitric oxide (NO) via mitochondrial aldehyde oxidoreductase. NO activates soluble guanylate cyclase (sGC) in vascular smooth muscle, raising intracellular cGMP concentrations. Elevated cGMP activates protein kinase G (PKG), leading to phosphorylation of myosin light chain kinase and inhibition of calcium influx, culminating in vasorelaxation. Coronary dilation reduces myocardial oxygen consumption, while venous pooling lowers preload and, consequently, wall stress.

Phosphodiesterase‑5 Inhibitors

These agents inhibit PDE5, preventing cGMP catabolism. The resulting rise in cGMP levels sustains PKG activation, promoting vasodilation predominantly in the coronary microcirculation. Clinical evidence suggests a modest improvement in exercise tolerance for refractory angina.

Ranolazine and Metabolic Modulators

Ranolazine selectively inhibits late sodium current (I_Na,late) in myocardial cells, reducing intracellular sodium and, via the Na⁺/Ca²⁺ exchanger, intracellular calcium overload. This mitigates diastolic wall tension and enhances coronary perfusion. The drug does not significantly alter heart rate or blood pressure, making it useful as an adjunct in patients intolerant to beta blockers or CCBs.

Other Agents

Nicorandil functions as a nitrate analog and ATP‑sensitive potassium channel opener; ivabradine selectively inhibits the funny current (I_f) in sinoatrial node cells, reducing heart rate without affecting contractility. Both mechanisms contribute to a reduction in myocardial oxygen demand.

Pharmacokinetics

Beta‑Adrenergic Receptor Antagonists

Oral absorption is generally rapid; first‑pass hepatic metabolism varies among agents, with propranolol showing extensive metabolism and metoprolol undergoing hepatic oxidation by CYP2D6. Elimination half‑lives range from 3–10 hours, and dosing adjustments are required in hepatic dysfunction. Renal excretion accounts for a minor fraction, except for atenolol, which is predominantly renally eliminated.

Calcium Channel Blockers

Dihydropyridines (e.g., amlodipine) exhibit high oral bioavailability (>90%) and undergo extensive hepatic metabolism via CYP3A4. Benzothiazepines (verapamil, diltiazem) have lower bioavailability (≈30–50%) and are metabolized by CYP3A4 and CYP2D6. Half‑lives range from 12 to 36 hours, permitting once‑daily dosing. Renal excretion is significant for verapamil and diltiazem; dose adjustments are advised in renal impairment.

Nitrates and Nitrate Prodrugs

Acetylsalicylic acid derivatives (e.g., nitroglycerin) exhibit rapid sublingual absorption; sustained‑release formulations provide steady plasma concentrations. Metabolism primarily occurs via mitochondrial aldehyde oxidoreductase and nitrate reductase pathways. Half‑lives are short (minutes to a few hours), necessitating multiple daily dosing or continuous infusion for chronic therapy.

Phosphodiesterase‑5 Inhibitors

Sildenafil is absorbed within 30–120 minutes, with a half‑life of approximately 3–5 hours. Metabolized by CYP3A4 and CYP2C9, it has a narrow therapeutic window. Renal and hepatic impairments reduce clearance, requiring dose reductions.

Ranolazine

Ranolazine demonstrates high oral bioavailability (~90%) and is metabolized by CYP3A4; a secondary pathway involves CYP2D6. The half‑life is approximately 12–15 hours, supporting once‑daily dosing. Renal excretion accounts for about 40% of elimination; dose adjustment is recommended if creatinine clearance falls below 30 mL/min.

Other Agents

Nicorandil is well absorbed orally, with a half‑life of 4–5 hours. It is metabolized to nicotinic acid and nicotinamide. Ivabradine exhibits rapid absorption and a half‑life of 3–4 hours; metabolism is mediated by CYP3A4 and CYP2C9.

Therapeutic Uses/Clinical Applications

Approved Indications

All antianginal classes are indicated for the prevention of exertional chest pain in stable angina, as part of secondary prevention in coronary artery disease, and for certain acute presentations (e.g., nitroglycerin for transient ischemia). Specific agents have additional approvals:

• Beta blockers: prevention of myocardial infarction recurrence, management of arrhythmias.
• CCBs: treatment of hypertension, migraine prophylaxis.
• Nitrates: acute angina relief, chronic angina management.
• Phosphodiesterase‑5 inhibitors: treatment of erectile dysfunction and pulmonary hypertension.
• Ranolazine: refractory angina not controlled by standard therapy.
• Nicorandil: refractory angina.
• Ivabradine: heart rate control in heart failure with reduced ejection fraction.

Off‑Label Uses

Beta blockers are frequently employed in patients with arrhythmias and hypertrophic cardiomyopathy. CCBs are used for vasospastic angina and migraine prophylaxis. Nitrates have been explored for migraine prophylaxis. Ranolazine is sometimes used in patients with chronic stable angina and heart failure with preserved ejection fraction. Nicorandil and ivabradine are occasionally prescribed for refractory angina when first‑line agents are contraindicated or poorly tolerated.

Adverse Effects

Common Side Effects

• Beta blockers: bradycardia, fatigue, dizziness, cold extremities, erectile dysfunction.
• CCBs: peripheral edema, flushing, headache, constipation, dizziness.
• Nitrates: headache, hypotension, tachyphylaxis, flushing, dizziness.
• Phosphodiesterase‑5 inhibitors: headache, flushing, dyspepsia, visual disturbances.
• Ranolazine: nausea, dizziness, constipation, headache.
• Nicorandil: headache, flushing, hypotension, nausea, vomiting.
• Ivabradine: visual phenomena (phosphenes), bradycardia, atrial fibrillation.

Serious or Rare Adverse Reactions

Beta blockers can precipitate bronchospasm in asthmatic patients and exacerbate heart failure in advanced stages. CCBs may cause severe hypotension, especially when combined with other vasodilators. Nitrates can lead to severe hypotension, reflex tachycardia, and, rarely, prolonged cyanosis. Phosphodiesterase‑5 inhibitors may induce priapism and sudden vision loss. Ranolazine has been associated with QT interval prolongation in susceptible individuals. Nicorandil may cause severe hypotension and is contraindicated in patients with severe renal impairment. Ivabradine is associated with atrial fibrillation and bradycardia, and may be contraindicated in sick sinus syndrome.

Black Box Warnings

Beta blockers: risk of worsening heart failure and bronchospasm; contraindicated in severe asthma and decompensated heart failure. CCBs: risk of severe hypotension; contraindicated in severe aortic stenosis. Nitrates: risk of cyanosis and severe hypotension; contraindicated in patients with severe renal impairment. Phosphodiesterase‑5 inhibitors: risk of sudden vision loss; contraindicated with nitrates. Ranolazine: QT prolongation; contraindicated in patients with known long QT syndrome. Nicorandil: severe hypotension; contraindicated in severe renal dysfunction. Ivabradine: contraindicated in sick sinus syndrome and severe bradycardia.

Drug Interactions

Beta‑Adrenergic Receptor Antagonists

Co‑administration with CYP2D6 inhibitors (e.g., fluoxetine) can increase plasma concentrations of metoprolol, elevating bradycardia risk. Concurrent use with other negative chronotropic agents (verapamil, diltiazem) may potentiate bradycardia and conduction disturbances. Anticoagulants (warfarin) may have altered pharmacodynamics due to overlapping hemodynamic effects.

Calcium Channel Blockers

Verapamil and diltiazem are potent CYP3A4 inhibitors, increasing serum levels of drugs metabolized by this pathway (e.g., simvastatin, amiodarone). Dihydropyridines can augment the hypotensive effect of nitrates and may interfere with the metabolism of digoxin, leading to toxicity. CCBs can reduce the absorption of orally administered drugs with poor water solubility.

Nitrates

Concurrent use of nitrates with phosphodiesterase‑5 inhibitors (e.g., sildenafil) can precipitate severe, potentially fatal hypotension. Nitrates may also potentiate the hypotensive effects of antihypertensives (ACE inhibitors, ARBs). Chronic nitrate therapy may induce tolerance, requiring nitrate‑free intervals.

Phosphodiesterase‑5 Inhibitors

Strong CYP3A4 inhibitors (ketoconazole, ritonavir) elevate sildenafil levels, increasing the risk of adverse events. Concurrent use with nitrates is contraindicated. Grapefruit juice can inhibit CYP3A4, raising sildenafil concentrations.

Ranolazine

Ranolazine is a CYP3A4 inhibitor, increasing levels of drugs such as clopidogrel, warfarin, and certain statins. It may also potentiate the effects of beta blockers and CCBs, leading to bradycardia or hypotension. Co‑administration with strong CYP3A4 inducers (rifampin) reduces ranolazine exposure.

Nicorandil and Ivabradine

Nicorandil’s nitrate component can interact with phosphodiesterase‑5 inhibitors. Ivabradine is metabolized by CYP3A4 and CYP2D6; strong inhibitors or inducers of these enzymes may alter its plasma concentrations. Co‑administration with beta blockers or CCBs may augment bradycardia risk.

Special Considerations

Use in Pregnancy and Lactation

Beta blockers cross the placenta and may cause fetal bradycardia, growth restriction, and neonatal hypoglycemia. Their use is generally discouraged unless benefits outweigh risks. CCBs are considered relatively safe in pregnancy but may lead to fetal growth restriction and neonatal hypotension. Nitrates are category B; caution is advised in early pregnancy. Phosphodiesterase‑5 inhibitors possess limited data and are contraindicated. Ranolazine and nicorandil have insufficient evidence; use is discouraged. Ivabradine is category C and should be avoided during pregnancy. Lactation may expose neonates to drug levels via breast milk; beta blockers and CCBs are excreted in small amounts but monitoring is recommended.

Pediatric and Geriatric Considerations

Beta blockers and CCBs are used in pediatric patients with congenital heart disease and arrhythmias, but dosing requires careful titration. Geriatric patients exhibit altered pharmacokinetics, including reduced hepatic clearance and increased sensitivity to hypotension, necessitating lower initial doses and slower titration. Polypharmacy increases interaction risk; medication reconciliation is essential.

Renal and Hepatic Impairment

Beta blockers with predominant renal excretion (atenolol, sotalol) require dose reduction in chronic kidney disease. Metoprolol and propranolol are metabolized hepatically; mild hepatic impairment may increase exposure modestly. CCBs with hepatic metabolism (verapamil, diltiazem) necessitate caution in hepatic failure. Nitrates are primarily metabolized hepatically; hepatic impairment may prolong effects. Ranolazine is renally cleared; a creatinine clearance <30 mL/min warrants dose adjustment. Nicorandil is contraindicated in severe renal impairment. Ivabradine’s metabolism is hepatic; hepatic dysfunction may elevate exposure.

Summary/Key Points

• Antianginal therapy targets myocardial oxygen supply and demand through diverse mechanisms: beta blockade, calcium channel blockade, nitrates, phosphodiesterase inhibition, and metabolic modulation.
• Beta blockers reduce heart rate and contractility, decreasing oxygen consumption but may worsen heart failure and bronchospasm.
• Calcium channel blockers primarily vasodilate coronary vessels, with dihydropyridines favoring peripheral vasodilation and phenylalkylamines exerting both vasodilatory and negative inotropic effects.
• Nitrates provide rapid vasodilation; tolerance development mandates nitrate‑free intervals.
• Ranolazine and nicorandil are valuable for refractory angina, acting through late sodium current inhibition and combined nitrate/KATP channel opening, respectively.
• Drug interactions are frequent due to shared metabolic pathways, notably CYP3A4; caution is required when combining agents such as nitrates with phosphodiesterase inhibitors.
• Special populations—pregnant patients, the elderly, those with renal or hepatic impairment—require individualized dosing and monitoring.
• Monitoring of heart rate, blood pressure, and potential signs of drug toxicity (e.g., bradycardia, hypotension, visual disturbances) is essential for safe therapy.

Mastery of the pharmacologic principles outlined herein will enable clinicians and pharmacists to tailor antianginal regimens, anticipate adverse events, and optimize therapeutic outcomes for patients with coronary artery disease.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.